Robeco Institutional Asset Management B.V. Sells 219,991 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Robeco Institutional Asset Management B.V. lessened its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 52.5% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 199,412 shares of the medical equipment provider's stock after selling 219,991 shares during the period. Robeco Institutional Asset Management B.V. owned about 0.10% of Zimmer Biomet worth $24,268,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in ZBH. Naples Money Management LLC bought a new stake in shares of Zimmer Biomet in the 4th quarter worth approximately $35,000. Activest Wealth Management lifted its position in shares of Zimmer Biomet by 410.4% during the 4th quarter. Activest Wealth Management now owns 342 shares of the medical equipment provider's stock valued at $42,000 after buying an additional 275 shares during the last quarter. Blue Trust Inc. grew its stake in shares of Zimmer Biomet by 48.4% during the 4th quarter. Blue Trust Inc. now owns 469 shares of the medical equipment provider's stock worth $52,000 after acquiring an additional 153 shares during the period. Quent Capital LLC increased its holdings in Zimmer Biomet by 21.6% in the 4th quarter. Quent Capital LLC now owns 518 shares of the medical equipment provider's stock worth $63,000 after acquiring an additional 92 shares during the last quarter. Finally, GAMMA Investing LLC bought a new stake in Zimmer Biomet in the 4th quarter valued at about $65,000. Institutional investors own 88.89% of the company's stock.

Insider Buying and Selling

In other news, VP Chad F. Phipps sold 26,156 shares of the business's stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $128.62, for a total value of $3,364,184.72. Following the completion of the sale, the vice president now owns 44,145 shares of the company's stock, valued at approximately $5,677,929.90. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 0.95% of the stock is owned by corporate insiders.

Zimmer Biomet Price Performance

Shares of ZBH traded down $1.05 during midday trading on Friday, reaching $120.18. The stock had a trading volume of 1,185,820 shares, compared to its average volume of 1,311,871. The company has a current ratio of 1.66, a quick ratio of 0.80 and a debt-to-equity ratio of 0.38. The company has a market capitalization of $24.72 billion, a price-to-earnings ratio of 26.01, a price-to-earnings-growth ratio of 2.19 and a beta of 1.03. The company's 50-day moving average is $124.33 and its 200 day moving average is $121.15. Zimmer Biomet Holdings, Inc. has a 12-month low of $102.00 and a 12-month high of $147.50.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.87 by $0.07. The business had revenue of $1.89 billion during the quarter, compared to analyst estimates of $1.87 billion. Zimmer Biomet had a return on equity of 12.70% and a net margin of 12.93%. Zimmer Biomet's revenue for the quarter was up 3.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.89 earnings per share. On average, equities analysts predict that Zimmer Biomet Holdings, Inc. will post 8.1 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, July 31st. Investors of record on Wednesday, June 26th will be given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.80%. The ex-dividend date of this dividend is Wednesday, June 26th. Zimmer Biomet's payout ratio is presently 20.78%.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on ZBH. JPMorgan Chase & Co. lifted their target price on shares of Zimmer Biomet from $115.00 to $125.00 and gave the stock a "neutral" rating in a research note on Friday, February 9th. Evercore ISI increased their target price on Zimmer Biomet from $125.00 to $130.00 and gave the stock an "in-line" rating in a research report on Thursday, April 4th. Barclays lifted their price target on Zimmer Biomet from $120.00 to $130.00 and gave the company an "underweight" rating in a research report on Monday, February 12th. Royal Bank of Canada reissued an "outperform" rating and set a $140.00 price objective on shares of Zimmer Biomet in a report on Friday, February 9th. Finally, Citigroup lifted their target price on Zimmer Biomet from $134.00 to $140.00 and gave the company a "neutral" rating in a report on Wednesday, April 3rd. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $135.40.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.